Effects of vedolizumab in patients with primary sclerosing cholangitis and inflammatory bowel diseases

Effects of vedolizumab in patients with primary sclerosing cholangitis and inflammatory bowel diseases

<p><strong>Background & Aims</strong> Gut-homing lymphocytes that express the integrin α4β7 and CCR9 might contribute to development of primary sclerosing cholangitis (PSC). Vedolizumab, which blocks the integrin α4β7, is used to treat patients with inflammatory bowel disea...

Полное описание

Библиографические подробности
Главные авторы:	Lynch, K, Chapman, R, Keshav, S, Montano-Loza, A, Mason, A, Kremer, A, Vetter, M, De Krijger, M, Ponsioen, C, Trivedi, P, Hirschfield, G, Schramm, C, Liu, C, Bowlus, C, Estes, D, Pratt, D, Hedin, C, Bergquist, A, De Vries, A, Janneke Van Der Woude, C, Yu, L, Assis, D, Boyer, J, Ytting, H, Hallibasic, E, Trauner, M, Marschall, H, Daretti, L, Marzioni, M, Yimam, K, Perin, N, Floreani, A, Beretta-Piccoli, B, Rogers, J, International Primary Sclerosing Cholangitis Study Group (IPSCSG), Levy, C
Формат:	Journal article
Язык:	English
Опубликовано:	Elsevier 2019

Схожие документы

International experience of vedolizumab in primary sclerosing cholangitis and inflammatory bowel disease
по: Williamson, K, и др.
Опубликовано: (2018)

Vedolizumab for the treatment of chronic pouchitis
по: Travis, S, и др.
Опубликовано: (2023)

Fecal calprotectin is an early predictor of endoscopic response and histologic remission after the start of vedolizumab in inflammatory bowel disease
по: Renske W. M. Pauwels, и др.
Опубликовано: (2020-12-01)

Subcutaneous vedolizumab interval extension in inflammatory bowel disease patients: a case series
по: Suzanne I. Anjie, и др.
Опубликовано: (2024-02-01)

Vedolizumab: Potential Mechanisms of Action for Reducing Pathological Inflammation in Inflammatory Bowel Diseases
по: Matthew Luzentales-Simpson, и др.
Опубликовано: (2021-02-01)

P571 Vedolizumab (VDZ) real-world outcomes in ulcerative colitis (UC)
по: Pulusu, S, и др.
Опубликовано: (2018)

Patient considerations in the management of ulcerative colitis – role of vedolizumab
по: Kothari M, и др.
Опубликовано: (2015-08-01)

Vedolizumab for inflammatory bowel diseasesI
по: Igor L. Khalif, и др.
Опубликовано: (2018-08-01)

Vedolizumab in the treatment of inflammatory bowel diseases: whom and how?
по: A. O. Golovenko, и др.
Опубликовано: (2018-10-01)

Vedolizumab as a Potential Culprit in the Development of Ovarian Teratoma?
по: Judy A. Trieu, и др.
Опубликовано: (2017-12-01)

Vedolizumab-Induced Liver Injury
по: Miguel Mascarenhas Saraiva, и др.
Опубликовано: (2020-12-01)

Vedolizumab in paediatric Inflammatory Bowel Disease: A retrospective multi-centre experience From the paediatric IBD Porto Group of ESPGHAN
по: Ledder, O, и др.
Опубликовано: (2017)

Vedolizumab in pediatric inflammatory bowel disease: a retrospective multi-center experience from the Paediatric IBD Porto group of ESPGHAN
по: Ledder, O, и др.
Опубликовано: (2017)

Long-term outcomes and predictors of vedolizumab persistence in ulcerative colitis
по: Beatriz Gros, и др.
Опубликовано: (2024-07-01)

Validation of the prognostic value of histologic scoring systems in primary sclerosing cholangitis: An international cohort study.
по: de Vries, E, и др.
Опубликовано: (2016)

Vedolizumab in Inflammatory Bowel Disease: West versus East
по: Prasanta Debnath, и др.
Опубликовано: (2021-01-01)

Protocol for the development of a core outcome set for clinical trials in primary sclerosing cholangitis
по: Martine Walmsley, и др.
Опубликовано: (2024-06-01)

Post-marketing experience of vedolizumab: Pneumonia and other respiratory tract infections
по: Bhayat, F, и др.
Опубликовано: (2017)

Vedolizumab in Pediatric inflammatory bowel diseases: a retrospective multi-center experience from the paediatric IBD Porto group of ESPGHAN
по: Ledder, O, и др.
Опубликовано: (2017)

Incidence of pneumonia and other respiratory tract infections with vedolizumab treatment: clinical trial experience
по: Feagan, B, и др.
Опубликовано: (2017)

Clinical efficacy of vedolizumab for inflammatory bowel disease
по: Liu Sixue, Zhong Wa, Lin Ying, Xia Zhongsheng, Zhong Yingqiang
Опубликовано: (2022-10-01)

Acute Chest Pain as an Infusion Reaction to Vedolizumab
по: Asaf Levartovsky, и др.
Опубликовано: (2022-06-01)

Post-marketing safety experience of vedolizumab in older patients with inflammatory bowel disease
по: Travis, S, и др.
Опубликовано: (2018)

Respiratory tract infections in patients with inflammatory bowel disease: safety analyses from vedolizumab clinical trials
по: Feagan, BG, и др.
Опубликовано: (2018)

Vedolizumab does not increase risk of clostridium difficile infection in patients with inflammatory bowel disease using vedolizumab: A retrospective cohort study
по: Abdulaziz Saad Alshahrani, и др.
Опубликовано: (2023-09-01)

Impact on the budget of ONLS program of vedolizumab introduction for the treatment of inflammatory bowel disease
по: S. K. Zyryanov, и др.
Опубликовано: (2018-05-01)

Vedolizumab more likely to be discontinued than ustekinumab in anti-TNF-experienced patients with fistulizing Crohn’s disease
по: Kira L. Newman, и др.
Опубликовано: (2023-03-01)

Therapeutic Drug Monitoring of Vedolizumab in Inflammatory Bowel Disease Patients during Maintenance Treatment—TUMMY Study
по: Merve Sivridaş, и др.
Опубликовано: (2023-03-01)

Vedolizumab for perianal fistulizing Crohn’s disease: systematic review and meta-analysis
по: Fares Ayoub, и др.
Опубликовано: (2022-04-01)

Introducing vedolizumab to clinical practice: who, when and how?
по: Bryant, R, и др.
Опубликовано: (2015)

A product review of vedolizumab in inflammatory bowel disease
по: Robert Battat, и др.
Опубликовано: (2019-10-01)

Vedolizumab in the treatment of inflammatory bowel disease: evolving paradigms
по: Benjamin Crooks, и др.
Опубликовано: (2020-03-01)

Incidence of pneumonia and other respiratory tract infections with vedolizumab treatment for inflammatory bowel disease: clinical trial experience
по: Feagan, B, и др.
Опубликовано: (2017)

Evaluating Efficacy of Vedolizumab, Ustekinumab, and Golimumab in the Management of Inflammatory Bowel Disease and the Combined Role of Nutritional Therapy with Biologics: A Review
по: Shahed Kamal, и др.
Опубликовано: (2024-08-01)

Post-marketing experience of vedolizumab in inflammatory bowel disease: analysis of pneumonia and other respiratory tract infections
по: Bhayat, F, и др.
Опубликовано: (2017)

Systematic review: the safety of vedolizumab for the treatment of inflammatory bowel disease.
по: Bye, W, и др.
Опубликовано: (2017)

Vedolizumab in Crohn Disease genesis-sefh drug evaluation report
по: Jenifer González Chávez, и др.
Опубликовано: (2015-09-01)

Ustekinumab and Vedolizumab Dual Biologic Therapy in the Treatment of Crohn’s Disease
по: Eddie Y. Liu, и др.
Опубликовано: (2017-01-01)

Take vedolizumab home: transition from intravenous to subcutaneous treatment
по: Kaituo Huang, и др.
Опубликовано: (2024-05-01)

Acquired hemophilia associated with vedolizumab in a patient with hemorrhagic rectocolitis
по: Thomas Schiestel
Опубликовано: (2023-03-01)